Biosimilar infliximab could offset access inequities in East European Crohn's patients
This article was originally published in Scrip
Executive Summary
Introduction of biosimilar Remicade (infliximab) to treat Crohn's disease is expected to provide substantial savings in six central and east European (CEE) countries. As Johnson & Johnson revealed the impact that the launch of Celltrion's Remsima is having on sales of Remicade, Hungarian health economists are forecasting that budget savings from use of the biosimilar, priced at just a 25% discount, could fund treatment in almost a third more patients.